10-year outcomes in localized prostate cancer: Authors' reply
We agree with Klotz and Kibel that the lack of significant differences in survival among the three treatments makes a comparison between radiotherapy and surgery unwise. The predetermined power calculation for the ProtecT trial estimated a prostate-cancer mortality rate of 10% at a median of 10 year...
| Asıl Yazarlar: | , , |
|---|---|
| Materyal Türü: | Journal article |
| Baskı/Yayın Bilgisi: |
Massachusetts Medical Society
2017
|
| _version_ | 1826297920605913088 |
|---|---|
| author | Hamdy, F Donovan, J Neal, D |
| author_facet | Hamdy, F Donovan, J Neal, D |
| author_sort | Hamdy, F |
| collection | OXFORD |
| description | We agree with Klotz and Kibel that the lack of significant differences in survival among the three treatments makes a comparison between radiotherapy and surgery unwise. The predetermined power calculation for the ProtecT trial estimated a prostate-cancer mortality rate of 10% at a median of 10 years, and because the observed rate was 1%, longer follow-up is required to evaluate differences. We agree that the ProtecT findings should not be interpreted as a case against active surveillance. The similar rates of survival in the three groups, the lower rate of symptoms in the active-monitoring group than in the radical-treatment groups, and the finding that 80% of the men in the active-monitoring group remained progression- free provide evidence to support this option. |
| first_indexed | 2024-03-07T04:38:58Z |
| format | Journal article |
| id | oxford-uuid:d0f49142-eda6-4c2f-a387-93e82c31e183 |
| institution | University of Oxford |
| last_indexed | 2024-03-07T04:38:58Z |
| publishDate | 2017 |
| publisher | Massachusetts Medical Society |
| record_format | dspace |
| spelling | oxford-uuid:d0f49142-eda6-4c2f-a387-93e82c31e1832022-03-27T07:53:39Z10-year outcomes in localized prostate cancer: Authors' replyJournal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:d0f49142-eda6-4c2f-a387-93e82c31e183Symplectic Elements at OxfordMassachusetts Medical Society2017Hamdy, FDonovan, JNeal, DWe agree with Klotz and Kibel that the lack of significant differences in survival among the three treatments makes a comparison between radiotherapy and surgery unwise. The predetermined power calculation for the ProtecT trial estimated a prostate-cancer mortality rate of 10% at a median of 10 years, and because the observed rate was 1%, longer follow-up is required to evaluate differences. We agree that the ProtecT findings should not be interpreted as a case against active surveillance. The similar rates of survival in the three groups, the lower rate of symptoms in the active-monitoring group than in the radical-treatment groups, and the finding that 80% of the men in the active-monitoring group remained progression- free provide evidence to support this option. |
| spellingShingle | Hamdy, F Donovan, J Neal, D 10-year outcomes in localized prostate cancer: Authors' reply |
| title | 10-year outcomes in localized prostate cancer: Authors' reply |
| title_full | 10-year outcomes in localized prostate cancer: Authors' reply |
| title_fullStr | 10-year outcomes in localized prostate cancer: Authors' reply |
| title_full_unstemmed | 10-year outcomes in localized prostate cancer: Authors' reply |
| title_short | 10-year outcomes in localized prostate cancer: Authors' reply |
| title_sort | 10 year outcomes in localized prostate cancer authors reply |
| work_keys_str_mv | AT hamdyf 10yearoutcomesinlocalizedprostatecancerauthorsreply AT donovanj 10yearoutcomesinlocalizedprostatecancerauthorsreply AT neald 10yearoutcomesinlocalizedprostatecancerauthorsreply |